More Events
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
pdf
2024 Press Release
Genomma Lab Internacional Announces Tenth Dividend Payment
December 16, 2024GENOMMA LAB PHARMA MANUFACTURING FACILITY GRANTED PENDING GMP CERTIFICATION FOR THE MEXICAN MARKET
October 2, 2024Genomma Lab Internacional Announces Ninth Dividend Payment
September 5, 2024External Auditor Ratification (Spanish Only)
August 9, 2024Genomma Lab Announces Strategic Bolt-On Acquisition of Four Brands
July 25, 2024Refinancing Of Long-Term Liabilities And Release Of Real Estate Collateral
July 22, 2024Genomma Lab Internacional Announces Eighth Dividend Payment
June 13, 2024Agreement Signed for Share Redemption in Marzam
May 3, 2024GENOMMA LAB INTERNACIONAL ANNOUNCES SEVENTH DIVIDEND PAYMENT
March 13, 2024MSCI Upgrades Genomma Lab’s ESG Rating to A; Third Rating Upgrade Obtained Over the Past 4 Years
February 28, 2024EFFECTS OF ARGENTINA HYPERINFLATIONARY ACCOUNTING ON Q4 AND FULL YEAR 2023 RESULTS
February 15, 20242024 Relevant Information
Genomma Lab Q3 2024 Earnings Release
October 23, 20243Q-2024 Earnings Call Advisory
October 2, 2024Genomma Lab Q2 2024 Earnings Release
July 24, 20242Q-2024 Earnings Call Advisory
July 2, 2024Genomma Lab Q1 2024 Earnings Release
April 24, 20241Q-2024 Earnings Call Advisory
April 8, 2024Genomma Lab Q4 & Full Year 2023 Earnings Release
February 21, 2024METHODOLOGY FOR THE EFFECTS OF ARGENTINA HYPERINFLATIONARY ACCOUNTING (IAS 29 & IAS 21)
February 15, 20244Q-2023 Earnings Call Advisory
January 23, 20242023 Press Release
GENOMMA LAB INTERNACIONAL ANNOUNCES SIXTH DIVIDEND PAYMENT
December 13, 2023Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America
November 29, 2023GENOMMA LAB INTERNACIONAL ANNOUNCES FIFTH DIVIDEND PAYMENT
September 19, 2023Unusual Movements in the Stock Price (Spanish Only)
August 17, 2023External Auditor Ratification (Spanish Only)
August 11, 2023Genomma Lab International informs the Voluntarily Prepayment of the Second Tranche of its IFC Secured Loan
August 8, 2023GENOMMA LAB MANUFACTURING FACILITY GRANTED COFEPRIS OPERATING LICENSE FOR ALL ITS PHARMA / OTC MANUFACTURING LINES
August 5, 2023Genomma Lab Internacional Announces Fourth Dividend Payment
June 2, 2023Prepayment of Long-term Unsecured Bond “LAB-20”
May 2, 2023GENOMMA LAB INTERNACIONAL ISSUED LAB23 & LAB 23-2 UNSECURED BONDS
April 27, 2023Retransmission of certain letters referred to External Auditors (Spanish Only)
March 27, 2023Unusual Movements in the Stock Price (Spanish Only)
February 23, 2023IFC and Genomma Lab signed a Multi-currency Long-term Loan
January 9, 20232023 Relevant Information
Genomma Lab Q3 2023 Earnings Release
October 25, 20233Q-2023 Earnings Call Advisory
October 4, 2023Our Progress Sustainability 2022
July 27, 2023Genomma Lab Q2 2023 Earnings Release
July 26, 2023Genomma Lab Q1 2023 Earnings Release
April 26, 20231Q-2023 Earnings Call Advisory
April 10, 2023Genomma Lab Q4 2022 Earnings Release
February 22, 20234Q-2022 Earnings Call Advisory
January 30, 20232022 Relevant Information
Genomma Lab to Host Investor Day and Site Visit on March 8, 2023 in Mexico
December 20, 2022Genomma Lab Q3 2022 Earnings Release
October 26, 20223Q-2022 Earnings Call Advisory
October 17, 2022Genomma Lab Q2 2022 Earnings Release
July 27, 20222Q-2022 Earnings Call Advisory
July 12, 2022Application of IAS-36 and IFRS-13 (PIR) effects on the “Investment of shares” and “Retained earnings”
April 27, 2022Genomma Lab Q1 2022 Earnings Release
April 27, 20221Q-2022 Earnings Call Advisory
April 19, 2022PROXY 2022 – Genomma Lab nominees for Board of Directors and Committees to serve from April 2022 to April 2023
April 15, 2022PROXY 2022 – Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
April 15, 2022PROXY 2022 – Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2022 Share Buyback Program
April 15, 2022PROXY 2022 – Genomma Lab informs the proposed amendment to article third of the corporate statutes
April 15, 2022Genomma Lab Q4 & Full Year 2021 Earnings Release
February 23, 20224Q-2021 Earnings Call Advisory
February 2, 20222022 Press Release
GENOMMA LAB INTERNACIONAL ANNOUNCES LEADERSHIP SUCCESSION PLAN
November 27, 2022Genomma Lab Internacional Announces Third Dividend Payment
October 26, 2022Unusual Movements in the Stock Price (Spanish Only)
October 20, 2022Unusual Movements in the Stock Price (Spanish Only)
October 6, 2022Unusual Movements in the Stock Price (Spanish Only)
September 15, 2022External Auditor Ratification
August 16, 2022Genomma Lab Achieves World Bank / IFC’s Edge (Green Building) Certification
July 25, 2022Genomma Lab Internacional Announces Second Dividend Payment
May 30, 20222021 Press Release
Genomma Lab Internacional Announces Dividend Payment
December 9, 2021Oramed and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine
November 18, 2021Genomma Lab Receives Good Manufacturing Practices (GMP) Certification
September 7, 2021External Auditor Ratification
August 4, 20212025 Sustainability Strategy “A commitment to the future”
March 3, 2021Corporate video about the start of operations in the Industrial Cluster
February 24, 2021Voluntary payment of taxes
February 24, 20212021 Relevant Information
Genomma Lab Q3 2021 Earnings Release
October 27, 20213Q-2021 Earnings Call Advisory
October 14, 2021Genomma Lab Q2 2021 Earnings Release
July 28, 20212Q-2021 Earnings Call Advisory
July 13, 2021Genomma Lab Q1 2021 Earnings Release
April 28, 2021PROXY 2021 – Genomma Lab nominees for Board of Directors and Committees to serve from April 2021 to April 2022
April 14, 2021PROXY 2021 – Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
April 14, 2021PROXY 2021 – Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2021 Share Buyback Program
April 14, 20211Q-2021 Earnings Call Advisory
April 13, 2021Genomma Lab Q4 2020 Earnings Release
February 24, 20214Q-2020 Earnings Call Advisory
February 4, 20212020 Press Release
Genomma Lab Internacional becomes a constituent of the “Dow Jones Sustainability MILA Pacific Alliance Index”
November 23, 2020External Auditor Ratification
November 10, 2020Unusual Movements in the Stock Price (Spanish Only)
October 29, 2020Prepayment of Long-term Unsecured Bond “LAB-18”
September 14, 2020Repurchase of Long-term Unsecured Notes “LAB-18”
September 4, 2020Issuance of LAB-20 Unsecured Bond
August 31, 2020Repurchase of Long-Term Unsecured Notes “LAB-18”
August 19, 2020Repurchase of Long-Term Unsecured Notes “LAB-18”
July 20, 2020Genomma Lab becomes a constituent of the “S&P/BMV Total Mexico ESG Index”
June 30, 2020Changes to Board of Directors and Committees
May 4, 2020Unusual Movements in the Stock Price (Spanish Only)
April 16, 2020Unusual Movements in the Stock Price (Spanish Only)
March 12, 20202020 Relevant Information
Genomma Lab Q3 2020 Earnings Release
October 21, 20203Q-2020 Earnings Call Advisory
October 13, 2020Genomma Lab Q2 2020 Earnings Release
July 22, 20202Q-2020 Earnings Call Advisory
July 14, 2020Genomma Lab Q1 2020 Earnings Release
April 22, 20201Q-2020 Earnings Call Advisory
April 20, 2020PROXY 2020 – Genomma Lab informs the amount to be proposed to the Shareholder’s Meeting for the 2020 Share Buyback Program
April 18, 2020PROXY 2020 – Genomma Lab informs the amount to be proposed of remuneration for the Board of Directors and The Audit & Corporate Practices Committee Members
April 16, 2020PROXY 2020 – Genomma Lab nominees for Board of Directors and Committees to serve from April 2020 to April 2021
April 16, 2020Genomma Lab Q4 & FY 2019 Earnings Release
February 26, 20204Q-2019 Earnings Call Advisory
February 4, 20202019 Relevant Information
3Q-2019 Earnings Call Advisory
October 16, 2019Non-Cash New IFRS Accounting Adjustments
April 29, 2019Proposed Terms and Amount for the Extension of the Revolving Debt Securities Program (Proxy)
April 16, 2019Proposed Amount of Remuneration for Board and Committee Members (Proxy)
April 16, 2019Proposed Amount for Share Buy Back Program at AGSM 2019 (Proxy)
April 16, 2019Proposed Special Delegates to Formalize Resolutions at the AGSM 2019 (Proxy)
April 16, 20191Q 2019 Results Release Conference Call
April 15, 2019Genomma Lab Earnings Release 4Q and FY 2018
February 26, 20194Q 2018 Results Release Conference Call
February 13, 20192019 Press Release
Prepayment Of Local Bond (CEBUR) LAB 14
September 30, 2019Genomma Lab Signs Exclusive License to Market NOVAMIL and NOVALAC in Mexico
September 12, 2019Placement of MX$300 Million Through Two Unsecured Local Bond Offerings
September 5, 2019Genomma´s OTC Manufacturing Plant Receives COFEPRIS Sanitary License
July 15, 20192017 Annual Report Retransmission (Spanish Only)
May 24, 20192018 Quarterly Financial Statements Restatement
May 1, 2019Changes to Board of Directors and Committees
April 30, 2019New Accounting Standards Impact
April 29, 2019Proxy Statements for Annual Shareholders Meeting (Spanish Only)
April 16, 2019Unusual Movements of Trading Volume of Lab (Spanish only)
January 29, 2019Exchange of Shares (Spanish only)
January 21, 20192018 Press Release
External Audit Ratification (Spanish Only)
October 26, 2018Genomma Lab Announces Management Changes
August 23, 2018Combined Financing Package by IFC and BID Invest
July 23, 2018Acquisition of US OTC Brands
June 14, 2018Payment of Lab 13 Local Bond
April 9, 2018Retransmition of 4Q17 Release
March 28, 2018Issuance of Local Bonds
March 23, 2018Companies Merger
March 23, 2018Unusual Movements of Lab (Spanish Only)
March 20, 20182018 Relevant Information
3Q18 Financial Information
October 24, 20182Q18 Conference Call Invite
July 26, 20182Q18 Financial Information
July 25, 20182017 10K (Spanish Only)
April 30, 2018Agreement for Voting Rights
April 25, 20181Q18 Financial Information
April 25, 2018Nominees for Board of Directors
April 5, 2018Agreement for Voting Rights
March 23, 20184Q17 Financial Information
February 21, 20182017 Relevant Information
3Q17 Conference Call Invite
October 26, 20172Q17 Financial Information (Spanish only)
June 30, 20173Q16 Financial Information (Spanish only)
June 2, 20174Q16 Financial Information (Spanish only)
June 2, 20172016 10K (Spanish Only)
April 28, 20171Q17 Conference Call
April 27, 2017Proxy: Valuation Report from Committee (Spanish Only)
April 22, 2017Proxy: Administrative Reorganization
April 16, 2017Proxy: Dividend. Amendment to Bylaws.
April 14, 2017Proxy: Nominees for Board of Directors
April 13, 20171Q17 Financial Information (Spanish only)
March 1, 20174Q16 Conference Call Invite
February 28, 20172017 Press Release
2016 Press Release
Genomma Day-2016 Details
November 3, 2016Changes to Legal Department
July 27, 2016Unusual Movements of Lab (Spanish Only)
April 29, 2016Changes in Board of Directors and Committees (Spanish Only)
April 29, 2016Unusual Movements of Lab (Spanish Only)
April 28, 2016Analyst Coverage (Spanish Only)
March 14, 2016Changes to Trust (Only Spanish)
March 14, 2016Unusual Movements of Lab (Spanish Only)
March 3, 2016Changes in Policies (Spanish only)
February 25, 2016Unusual Movements of Lab (Spanish Only)
January 22, 2016Unusual Movements of Lab (Spanish Only)
January 21, 20162016 Relevant Information
Genomma Day 2016 Presentation
November 3, 20162Q16 Financial Information (Spanish only)
July 27, 2016Corporate Presentation June 2016
June 1, 20164Q15 Financial Information (Spanish only)
April 29, 20162015 10K (Spanish only)
April 28, 20161Q16 Financial Information (Spanish only)
April 27, 20164Q15 Conference Call Invite
February 25, 20162015 Press Release
Organizational Changes
December 2, 2015Sale of Marzam and Information on Genomma Day
September 29, 2015Approval from Cofece to Sell Marzam
August 25, 2015Sale of Majority Stake of Grupo Marzam
June 22, 2015Changes to Board of Directors and Committees
April 15, 20151Q15 Earnings Preview
April 1, 2015Proposals for Annual General Shareholders Meeting
March 30, 2015Expansion and Extension of Walgreens Partnership
March 20, 20152015 Relevant Information
3Q15 Financial Information (Spanish Only)
October 28, 2015Corporate Presentation September 2015
September 29, 20152Q15 Financial Information (Spanish Only)
July 23, 20151Q15 Financial Information (Spanish Only)
April 29, 20154Q14 Financial Information (Spanish Only)
April 14, 20152014 10K (Spanish Only)
March 26, 2015Genomma Lab 2015 Outlook
March 11, 20152014 Press Release
Changes in the Organizational Structure
December 11, 2014LAB 14 Debt Certificates Supplement (Spanish Only)
November 28, 2014Third Issuance of Debt Certificates
November 28, 2014Trust for Marzams New Distribution Model
October 6, 2014Closing of Marzam Transaction
June 30, 2014Strengthening of Commecial Department
March 31, 2014Acquisition of a Participation in Marzam
March 10, 20142014 Guidance and International Strategy
January 13, 20142014 Relevant Information
Genomma Day Presentation
November 7, 20143Q14 Corporate Presentation
November 7, 20143Q14 Financial Information (Spanish Only)
October 23, 20142Q14 Financial Information (Spanish Only)
July 24, 20144Q13 Financial Information (Spanish Only)
April 30, 20142013 10K (Spanish only)
April 30, 20141Q14 Financial Information (Spanish Only)
April 29, 20142013 Relevant Information
2013 Press Release
LAB 13-2 Debt Certificates Supplement (Spanish Only)
October 3, 2013Second Issuance of Debt Certificates
October 3, 2013Acquisition of a Package of OTC Brands
September 17, 2013Debt Certificates Geographic Distribution (Spanish Only)
July 15, 2013Debt Certificates Supplement (Spanish only)
July 8, 2013Issuance of Debt Certificates
July 8, 2013Definitive Prospectus (Spanish Only)
July 7, 2013Corporate Ratings
June 10, 2013Losec A Licensing Agreement
May 20, 2013Wal-Mart – TCP Announcement
February 18, 2013Signature of Agreement to Acquire Tafirol
January 25, 20132013 Guidance
January 14, 20132012 Relevant Information
2012 Press Release
2012 Guidance Review
September 20, 2012Acquisition of a package of brands
June 28, 2012Decision not to Pursue Acquisition of PBH
May 3, 2012GLI Secures Committed Financing to Acquire PBH
April 30, 2012Genomma Lab and PBH Updated Presentation
April 26, 2012New Lines of Products GB
April 23, 2012Changes in Auditing Committee (Spanish Only)
March 29, 2012GL to nominate PBH Slate of Directors
March 15, 2012Prestige Brands Holding Acquisition Rationale
February 28, 2012PR proposal Prestige Brands
February 21, 2012Entrance to IPC Sustainability Index
January 31, 2012Walgreens – TCP Announcement
January 18, 20122011 Press Release
Guidance-2012 December
December 30, 2011Closing of 2ndtranch of Acquisition from Colgate
December 21, 2011Acquisition of Brands from Colgate-Palmolive
October 2, 2011Termination XL3 Licence Agreement
May 27, 2011Genomma Lab Announces the Closing of a Financing A
April 1, 20112011 Relevant Information
2010 Press Release
2011 Earnings Guidance
December 10, 2010Licensing Agreement XL-3 Brand
November 19, 2010Changes in Controlling Trust
October 28, 2010Acquisition Package
October 21, 2010Banco Invex, S.A. Reduces it´s Equity Stake (Spanish Only)
June 23, 2010Package of Acquisitions
June 18, 2010External Auditors Report (Spanish Only)
April 28, 2010IFRS Adopting Process (Spanish Only)
April 22, 2010Variations in Operating Volume of GLI Stock (Spanish Only)
April 21, 2010ZN Mexico II, L.P. Reduces it´s Equity Stake in GLI (Spanish Only)
February 25, 20104Q09 Retransmission (Spanish Only)
February 24, 2010Variations in Operating Volume of GLI Stock
January 19, 2010Primer Nivel Generic Products (Spanish Only)
January 14, 20102010 Relevant Information
3Q10 Financial Information (Spanish Only)
October 27, 20102Q10 Financial Information (Spanish Only)
July 27, 20101Q10 Financial Information (Spanish Only)
April 23, 20102009 10K (Spanish Only)
April 22, 2010Conference Call Invitation 1Q10
April 13, 20104Q09 Retransmision (Spanish Only)
February 24, 20104Q09 Financial Information (Spanish Only)
February 24, 20102009 Press Release
GLI Announces its 2010 Earnings Guidance
December 11, 2009ZN Mexico l.p. Reduces its Equity Stake in Genomma
December 7, 2009Variations Operating Volume GLI Stock
November 30, 2009Variations Operating Volume GLI Stock
October 20, 2009Strategic Alliance Televisa and GLI
October 9, 2009Variations Operating Volume GLI Stock (Spanish Only)
October 2, 2009GLI Revises-2009 Earnings Guidance
September 8, 2009Reforma de Estatutos Sociales (Only Spanish)
September 4, 2009Strategic Alliance Between Televisa and GLI
August 29, 2009GLI Announces Brand Primer Nivel por tu Salud
August 12, 2009GLI Announces Changes Organizational Structure
July 28, 2009GLI Announces Change of Market Maker
July 17, 2009Acquisition of Sanborns Brands
July 5, 2009Acquisition of the Jockey Club Brand
June 5, 2009Dictum Transcription (Spanish Only)
May 6, 2009Purchase of 100% of MMN Stock (Spanish Only)
April 1, 2009Variation in Stocks Operating Volume
March 31, 2009Variation in Stocks Operating Volume (Spanish Only)
March 27, 20094Q09 Expectations (Spanish Only)
January 13, 2009New Market Maker Figure (Spanish Only)
January 12, 20092009 Relevant Information
2008 Press Release
